Last 12 months
Inside the activity.
7 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 4 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 3 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2022 Filed Jun 10, 2022 15:34 UTC |
Papapetropoulos SpyrosDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016402 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: Subject to vesting whereby all of the shares subject to the award will vest on the one year anniversary of June 8, 2023. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 15:32 UTC |
Jene Jill M.Director
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.92 Strike: $0.92 | $20,240.00 |
DisclosureSEC source: 0001493152-22-016399 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: (1) 100% vesting one year from date of grant. Read SEC document |
| May 17, 2022 Filed May 17, 2022 20:58 UTC |
Fogarty KristaPrincipal Accounting Officer
|
PurchaseCommon Stock | 12,500 | $0.86 | $10,750.00 |
DisclosureSEC source: 0001493152-22-014199 · ownership.xml · nonDerivative · entry 1 Fogarty Krista · CIK 0001906986 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Read SEC document |
| May 16, 2022 Filed May 16, 2022 22:44 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 50,000 | $0.77 | $38,495.00 |
DisclosureSEC source: 0001493152-22-014014 · ownership.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,303,090 Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 21:00 UTC |
Papapetropoulos SpyrosDirector
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.16 Strike: $1.16 | $11,600.00 |
DisclosureSEC source: 0001493152-22-009718 · ownership.xml · derivative · entry 1 Papapetropoulos Spyros · CIK 0001832694 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of April 11, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| April 11, 2022 Filed Apr 12, 2022 20:57 UTC |
Jene Jill M.Director
|
GrantStock Option (Right to Buy) · Derivative | 10,000 | $1.16 Strike: $1.16 | $11,600.00 |
DisclosureSEC source: 0001493152-22-009716 · ownership.xml · derivative · entry 1 Jene Jill M. · CIK 0001742105 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-11 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of April 11, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| January 03, 2022 Filed Jan 3, 2022 22:33 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 287,500 | $1.09 Strike: $1.09 | $313,375.00 |
DisclosureSEC source: 0001493152-22-000154 · ownership.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,500 Underlying: Common Stock · 287,500 shares Expires 2032-01-03 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 3, 2023, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:00 UTC |
BROWN MORGAN RChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 176,000 | $1.12 Strike: $1.12 | $197,120.00 |
DisclosureSEC source: 0001493152-21-030817 · ownership.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,000 Underlying: Common Stock · 176,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| December 07, 2021 Filed Dec 8, 2021 21:00 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 125,000 | $1.12 Strike: $1.12 | $140,000.00 |
DisclosureSEC source: 0001493152-21-030818 · ownership.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 7, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorate basis over the following two years. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 00:23 UTC |
Patel Mahesh V.Director · CEO and President
|
PurchaseCommon Stock | 25,000 | $1.09 | $27,250.00 |
DisclosureSEC source: 0001493152-21-029268 · ownership.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,253,090 Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:44 UTC |
Ono Richard DanaDirector
|
GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000539 · doc4_7261.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:43 UTC |
Higuchi John W.Director
|
GrantCommon Stock (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000538 · doc4_7260.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 18:42 UTC |
Fink Jeffrey ArvinDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $1.26 Strike: $1.26 | $27,720.00 |
DisclosureSEC source: 0001638599-21-000537 · doc4_7259.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 02:02 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 275,000 | $1.43 Strike: $1.43 | $393,250.00 |
DisclosureSEC source: 0001638599-21-000014 · doc4_6979.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-01-04 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 4, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. F1 · derivative.expiration_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 4, 2022, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 19:09 UTC |
Higuchi John W.Director
|
SaleCommon Stock | 5,000 | $1.35 | $6,767.00 |
DisclosureSEC source: 0001638599-21-000003 · doc4_6977.xml · nonDerivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 693,548 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 19:09 UTC |
Higuchi John W.Director
|
SaleCommon Stock | 1,700 | $1.35 | $2,286.50 |
DisclosureSEC source: 0001638599-21-000003 · doc4_6977.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,548 Read SEC document |
| December 28, 2020 Filed Dec 29, 2020 20:27 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
OtherStock Option (Right to Buy) · Derivative | 275,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001638599-20-000995 · doc4_6974.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 275,000 shares Expires 2030-12-15 F1 · kind: On December 15, 2020, the issuer granted to the reporting person, under the issuer's stock incentive plan, options to purchase 375,000 shares of the issuer's common stock. On December 28, 2020, the issuer rescinded and cancelled 275,000 of the options granted, for no consideration. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC |
BROWN MORGAN REVP and CFO
|
Exercise / conversionRestricted Stock Unit · Derivative | 28,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,125 Underlying: Common Stock · 28,125 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC |
BROWN MORGAN REVP and CFO
|
SaleCommon Stock | 8,437 | $1.35 | $11,389.95 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,504 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:05 UTC |
BROWN MORGAN REVP and CFO
|
Exercise / conversionCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 16:06 UTC |
HILL STEPHEN ADirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000978 · doc4_6961.xml · derivative · entry 2 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 16:06 UTC |
HILL STEPHEN ADirector
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000978 · doc4_6961.xml · nonDerivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Higuchi John W.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000981 · doc4_6964.xml · derivative · entry 2 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Higuchi John W.Director
|
Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000981 · doc4_6964.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Ono Richard DanaDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000980 · doc4_6963.xml · derivative · entry 2 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Stock · 5,250 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Ono Richard DanaDirector
|
Exercise / conversionCommon Stock | 5,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000980 · doc4_6963.xml · nonDerivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:06 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 45,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000977 · doc4_6960.xml · derivative · entry 4 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:06 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
SaleCommon Stock | 15,000 | $1.35 | $20,250.00 |
DisclosureSEC source: 0001638599-20-000977 · doc4_6960.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,228,090 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:06 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000977 · doc4_6960.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F3 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Fink Jeffrey ArvinDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000979 · doc4_6962.xml · derivative · entry 2 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 5,625 shares Expires 2027-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. F2 · derivative.expiration_date: Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO. Read SEC document |
| December 16, 2020 Filed Dec 17, 2020 21:07 UTC |
Fink Jeffrey ArvinDirector
|
Exercise / conversionCommon Stock | 5,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000979 · doc4_6962.xml · nonDerivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:05 UTC |
BROWN MORGAN REVP and CFO
|
GrantStock Options (Right to Buy) · Derivative | 160,000 | $1.37 Strike: $1.37 | $219,200.00 |
DisclosureSEC source: 0001638599-20-000976 · doc4_6959.xml · derivative · entry 3 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2030-12-15 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:06 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 375,000 | $1.37 Strike: $1.37 | $513,750.00 |
DisclosureSEC source: 0001638599-20-000977 · doc4_6960.xml · derivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2030-12-15 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC |
BROWN MORGAN RChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 70,754 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · derivative · entry 5 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,754 Underlying: Common Stock · 70,754 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC |
BROWN MORGAN RChief Financial Officer
|
Exercise / conversionCommon Stock | 70,754 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 3 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 122,978 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000949 · doc4_6948.xml · derivative · entry 5 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,978 Underlying: Common Stock · 122,978 shares Expires 2029-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2020 Filed Dec 8, 2020 21:50 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 122,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000949 · doc4_6948.xml · nonDerivative · entry 3 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,198,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
BROWN MORGAN RChief Financial Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 57,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · derivative · entry 4 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 57,500 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. F4 · derivative.expiration_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
BROWN MORGAN RChief Financial Officer
|
SaleCommon Stock | 17,250 | $1.57 | $27,023.85 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 2 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,062 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $1.54 - $1.60. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
BROWN MORGAN RChief Financial Officer
|
Exercise / conversionCommon Stock | 57,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000948 · doc4_6947.xml · nonDerivative · entry 1 BROWN MORGAN R · CIK 0001266062 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 145,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000949 · doc4_6948.xml · derivative · entry 4 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2028-12-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. F4 · derivative.expiration_date: Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
SaleCommon Stock | 43,500 | $1.57 | $68,134.05 |
DisclosureSEC source: 0001638599-20-000949 · doc4_6948.xml · nonDerivative · entry 2 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,112 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average price of shares sold at a price that ranged from $1.53 - $1.60 Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 21:50 UTC |
Patel Mahesh V.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 145,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-20-000949 · doc4_6948.xml · nonDerivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · shares: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. F1 · price: Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 16:11 UTC |
HILL STEPHEN ADirector
|
GrantStock Options (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000593 · doc4_6751.xml · derivative · entry 1 HILL STEPHEN A · CIK 0001237404 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:11 UTC |
Fink Jeffrey ArvinDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000592 · doc4_6752.xml · derivative · entry 1 Fink Jeffrey Arvin · CIK 0001595930 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:11 UTC |
Higuchi John W.Director
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000594 · doc4_6750.xml · derivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 20:10 UTC |
Ono Richard DanaDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.96 Strike: $0.96 | $21,183.80 |
DisclosureSEC source: 0001638599-20-000591 · doc4_6753.xml · derivative · entry 1 Ono Richard Dana · CIK 0001595989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: 100% vesting one year from date of grant Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 15:20 UTC |
Higuchi John W.Director
|
PurchaseCommon Stock | 220,000 | $0.32 | $69,542.00 |
DisclosureSEC source: 0001638599-20-000313 · doc4_6603.xml · nonDerivative · entry 1 Higuchi John W. · CIK 0001579891 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 696,498 F1 · price: Represents the average price of shares purchased at prices that ranged from $0.3111 - $0.328. Read SEC document |
| January 28, 2020 Filed Jan 28, 2020 21:26 UTC |
BROWN MORGAN REVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 132,000 | $0.46 Strike: $0.46 | $60,456.00 |
DisclosureSEC source: 0001638599-20-000106 · doc4_6488.xml · derivative · entry 1 BROWN MORGAN R · CIK 0001266062 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,000 Underlying: Common Stock · 132,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 28, 2021, while the remaining 2/3 of the shares subject to the award vest monthly on a prorata basis over the following two years. Read SEC document |
| January 28, 2020 Filed Jan 28, 2020 21:26 UTC |
Patel Mahesh V.Director · CEO and President
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.46 Strike: $0.46 | $137,400.00 |
DisclosureSEC source: 0001638599-20-000105 · doc4_6489.xml · derivative · entry 1 Patel Mahesh V. · CIK 0001579872 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of January 28, 2021, while the remaining 2/3 of the shares subject to the award vest monthly on a prorata basis over the following two years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.